Rx Product News (September 2018)

SEPTEMBER 15, 2018

DONNATAL ELIXER

MANUFACTURED BY: VistaPharm
INDICATION: Donnatel Elxer is indicated as an adjunctive therapy to treat enterocolitis and irritable bowel syndrome. VistaPharm has launched individual dose-cups of Donnatal Elixer in packages of 10, allowing pharmacists to purchase the treatment as needed. New convenient packaging will allow pharmacists to manage how much of the product is wasted and reallocate the time used to measure individual doses.
DOSAGE FORM: Liquid elixir
FOR MORE INFORMATION: donnatal.com/about-donnatal/donnatal-elixir/


SYMTUZA
MANUFACTURED BY: Janssen Scientific Affairs
INDICATION: FDA officials recently approved Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, tenofovir alafenamide 10 mg) to treat HIV 1 in patients who have not previously received treatment for HIV or patients who have been treated with a stable antiretroviral therapy for 6 months or longer and whose viral load is considered suppressed. Health care providers should monitor patients’ liver function before and during treatment, as Symtuza can worsen hepatitis B infections.
DOSAGE FORM: Tablets
FOR MORE INFORMATION: symtuzahcp.com


ORILISSA
MANUFACTURED BY: Abbvie
INDICATION: The FDA has approved Orilissa (egalolix) to treat moderate to severe endometriosis pain in women. The oral gonadotropin-releasing hormone (GnRH) was developed specifically to treat pain caused by the uterine disorder, making it the first of its kind. Orilissa is not recommended for patients who are pregnant or trying to become pregnant or patients with osteoporosis, as it may be associated with reduced bone density.
DOSAGE FORM: Oral
FOR MORE INFORMATION: abbvie.com




KRINTAFEL
MANUFACTURED BY: GlaxoSmithKline
INDICATION: The FDA recently approved Krintafel (tafenoquine), under priority review, to prevent Plasmodium vivax (P vivax) malaria relapse in patients who are receiving antimalarial treatment. The novel treatment is derived from 8-aminoquoline, and it is the first treatment of its kind approved in more than 60 years. Krintafel protects against every stage of the P vivax parasitic infection, including the period where it remains dormant in the liver, known as hypnozoite. Targeting hypnozoite can prevent the relapse of infection that can occur years after the initial infection.
DOSAGE FORM: Oral tablet
FOR MORE INFORMATION: gsk.com/en-gb/products/


 

SHARE THIS
0